Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Free Cash Flow (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Free Cash Flow for 2 consecutive years, with -$25.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 13.8% to -$25.6 million in Q4 2025 year-over-year; TTM through Oct 2025 was -$113.6 million, a 71.8% decrease, with the full-year FY2025 number at -$100.5 million, down 19.04% from a year prior.
  • Free Cash Flow was -$25.6 million for Q4 2025 at Kestra Medical Technologies, up from -$34.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$19.1 million in Q2 2024 to a low of -$34.4 million in Q3 2025.